TSBX (TSBX)
Turnstone Biologics Corp.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
USTurnstone Biologics Corp. is a clinical-stage biotechnology firm dedicated to developing therapeutic and curative treatments for patients battling solid tumor cancers.
Its leading investigational drug, TIDAL-01, is currently undergoing Phase 1 clinical trials for indications such as breast cancer, colorectal cancer, and uveal melanoma. This compound is also being assessed in an investigator-sponsored trial to address cutaneous and non-cutaneous melanomas. Furthermore, the company is advancing TIDAL-02, which is in preclinical development for treating various solid tumors. Turnstone Biologics was established in 2014 and maintains its headquarters in La Jolla, California.
Leadership
Michael Burgess, MBChB, Ph.D.
Interim Chief Medical Officer and Director
Sammy Farah, M.B.A., Ph.D.
President, Chief Executive Officer and Director
Saryah Azmat
Chief Operating Officer & Corporate Secretary
Stewart Abbot, Ph.D.
Chief Scientific Officer
Employees
--
Country
US
Sector
Healthcare
Website
turnstonebio.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Gupta Rishi | Director | Withholding/Transfer | 3.10M | -- | Aug 8, 2025 |
 ORBIMED ADVISORS LLC | Director | Withholding/Transfer | 3.10M | -- | Aug 8, 2025 |
 Versant Ventures V, LLC | 10% Owner | Withholding/Transfer | 2.73M | -- | Aug 8, 2025 |
| Versant Ventures V, LLC | 10% Owner | Withholding/Transfer | 207.5K | -- | Aug 8, 2025 |
| Versant Ventures V, LLC | 10% Owner | Withholding/Transfer | 90.9K | -- | Aug 8, 2025 |
| Versant Ventures V, LLC | 10% Owner | Withholding/Transfer | 82.0K | -- | Aug 8, 2025 |
Insiders
- Gupta RishiDirector
- ORBIMED ADVISORS LLCDirector
- Versant Ventures V, LLC10% Owner
- Jerel DavisDirector
US30d Avg
--
60d Avg
--
90d Avg
--